Generic Medicine Info
Should be taken with food.
Severe renal and hepatic impairment.
Special Precautions
Patient with CV disease (e.g. immediate post-MI period, new-onset atrial fibrillation, 2nd degree heart block or greater, unstable angina pectoris, CHF, sick sinus syndrome, bradycardia, or other supraventricular cardiac conduction abnormalities); uncorrected electrolyte disturbances (e.g. hyper- or hypokalaemia); history of seizure disorders; Parkinson's disease; asthma, COPD, active pulmonary infections (e.g. pneumonia); bladder outlet obstruction or prostatic hyperplasia; gastrointestinal obstruction or recovering from gastrointestinal surgery; risk factors for ulcer disease (e.g. history of ulcer, concomitant NSAID use). Moderate renal and mild to moderate hepatic impairment. Elderly. Pregnancy and lactation. CYP2D6 poor metabolisers. Patient Counselling This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Monitor body weight; mental status; symptoms of active or occult gastrointestinal bleeding, gastrointestinal intolerance, and cholinergic crisis.
Adverse Reactions
Significant: Serious skin reactions (e.g. Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, erythema multiforme), CNS depression, vagotonic effects on heart rate (e.g. bradycardia, atrioventricular node block), weight loss, seizures, increase gastric acid secretion, bladder outflow obstruction, BPH symptoms exacerbation. Cardiac disorders: Palpitations. Ear and labyrinth disorders: Tinnitus. Eye disorders: Blurred vision. Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhoea, dyspepsia. General disorders and administration site conditions:Fatigue, asthenia, malaise, lethargy. Injury, poisoning and procedural complications: Fall, laceration. Investigations: Increased hepatic enzymes. Metabolism and nutrition disorders: Decreased appetite, dehydration. Musculoskeletal and connective tissue disorders: Muscle spasms, muscle weakness. Nervous system disorders: Headache, dizziness, somnolence, syncope, tremor. Psychiatric disorders: Depression, hallucination. Skin and subcutaneous tissue disorders: Hyperhidrosis. Vascular disorders: Hypertension, flushing.
Drug Interactions
Increased bioavailability and risk of cholinergic adverse effects with potent CYP2D6 inhibitors (e.g. quinidine, paroxetine, fluoxetine); and CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, erythromycin). Additive effects with other cholinomimetics (e.g. ambenonium, donepezil, neostigmine, pyridostigmine, rivastigmine, systemic pilocarpine). May antagonise anticholinergic effects of atropine.
ATC Classification
N06DA04 - galantamine ; Belongs to the class of anticholinesterases. Used in the management of dementia.
Disclaimer: This information is independently developed by CIMS based on galantamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in